An interventional study of TheaLoz Duo Eyedrop in Dry Eye Syndromes and Computer Vision Syndrome, sponsored by Aston University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Aston University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Dry Eye Syndromes with a site in United Kingdom — 4 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · United Kingdom.
Among the 32 studies in Dry Eye Syndromes with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2024, is one of 19 with no phase, and was the 27th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →4 of the 32 studies in Dry Eye Syndromes with a site in United Kingdom are open now. Recruiting first, the newest first:
Aston University · Sites in United Kingdom
Ages 18+
Aston University · Sites in United Kingdom, New Zealand
Ages 18+
University of Plymouth · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 4
First in 2007; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 50 across the 29 interventional studies, 314 across the 3 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 32 have an industry lead sponsor. The 10 most frequent:
Aston University is the lead sponsor of 27 studies on the registry; 8 are open to participants now.
Aston University has 9 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Dry Eye Syndromes with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06163989Aston UniversityProtecting the Eyes of Gamers With Lubricating Eyedrops | 2026-12-30 |
| NCT07895849University of PlymouthPerformance Evaluation of the OCUTOP Hand-held Corneal Topographer | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Dry Eye Syndromes with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The excessive use of screens particularly amongst digital gamers can adversely impact the health of the surface of the eyes with symptoms and signs of surface damage. While strategies including limiting screen time exist, these may be ineffective given the widespread rise of digital device use and gaming culture in the modern era. There is limited evidence for the protective effect of lubricating eyedrops on the ocular surface for handheld console and computer gamers.
The aim of this study is to investigate the protective effect of a lubricating eyedrop (TheaLoz Duo) on the surface of the eyes in handheld console and computer gamers. The main question it aims to answer is whether TheaLoz Duo could protect the surface of the eyes from dessication and alleviate symptoms of dry eye disease in handheld console and computer gamers.
Participants will receive either the lubricating eyedrop first for 1 month, followed by a control condition (no eyedrops) for another month, or the other way round. Participants will attend 3 visits in total, each separated by 1 month apart. During each visit, routine clinical assessments of the front of the eye will be conducted. Subsequent findings from this timely study will help improve care of the surface of the eyes for a growing population of gamers worldwide.
This study will be a randomized, outcome assessor-masked, cross-over clinical study to assess the potential impact of TheaLoz Duo lubricating eyedrop on symptoms and signs of dry eye disease in handheld console and computer gamers. All visits will be conducted at the Aston Dry Eye Clinic in Aston University, Birmingham, United Kingdom.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The TheaLoz Duo eyedrop will be prescribed and used by the participant for 1 month. At the second visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle, and no eyedrops will be prescribed, and the participant monitored following 1 month. At the third and final visit 1 month later, the participant will return for a follow-up visit.
Drug: TheaLoz Duo Eyedrop
No eyedrops will be prescribed and the participant monitored for 1 month. At the second visit 1 month later, the participant will return and be prescribed TheaLoz Duo eyedrop and used by the participant for another 1 month. At the third and final visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle and complete the study visits.
Drug: TheaLoz Duo Eyedrop
TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
Also known as: Treatment Eyedrop
Change from Baseline in Ocular Surface Disease Index scores to the First Follow-Up 1 Month After Baseline
Validated questionnaire for assessing dry eye symptom severity and impact. Scores range from 0 indicating no dry eye symptoms to 100 with severe dry eye symptoms and impact (Schiffman et al, 2000).
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Ocular Surface Disease Index scores to the Second Follow-Up 1 Month After the First Follow-Up
Validated questionnaire for assessing dry eye symptom severity and impact. Scores range from 0 indicating no dry eye symptoms to 100 with severe dry eye symptoms and impact (Schiffman et al, 2000).
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Computer Vision Syndrome Questionnaire scores to the First Follow-Up 1 Month After Baseline
Validated questionnaire for assessing the severity and frequency of eye strain when using a computer. The scores range from 0 to 32 (Seguí Mdel et al, 2015).
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Computer Vision Syndrome Questionnaire scores to the Second Follow-Up 1 Month After the First Follow-Up
Validated questionnaire for assessing the severity and frequency of eye strain when using a computer. The scores range from 0 to 32 (Seguí Mdel et al, 2015).
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Visual Acuity to the First Follow-Up 1 Month After Baseline
Subjective measure of visual acuity using Logarithm of the Minimum Angle Resolution (logMAR) scoring, ranging from -0.30 which signify the ability to be able to resolve the smallest letters, to 1.00 which signify the ability to resolve only the largest letters.
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Visual Acuity to the Second Follow-Up 1 Month After the First Follow-Up
Subjective measure of visual acuity using Logarithm of the Minimum Angle Resolution (logMAR) scoring, ranging from -0.30 which signify the ability to be able to resolve the smallest letters, to 1.00 which signify the ability to resolve only the largest letters.
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Tear Meniscus Height to the First Follow-Up 1 Month After Baseline
Measure of the volume of tears in mm using the Oculus Keratograph 5M instrument. An average of 3 measurements is obtained.
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Tear Meniscus Height to the Second Follow-Up 1 Month After the First Follow-Up
Measure of the volume of tears in mm using the Oculus Keratograph 5M instrument. An average of 3 measurements is obtained.
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Lipid Layer Pattern to the First Follow-Up 1 Month After Baseline
Subjective grading of the appearance of the lipid layer pattern as a surrogate measure of its thickness using the Oculus Keratograph 5M instrument. This ranges from Grade 1 indicating very thin lipid layer to Grade 6 indicating very thick lipid layer.
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Lipid Layer Pattern to the Second Follow-Up 1 Month After the First Follow-Up
Subjective grading of the appearance of the lipid layer pattern as a surrogate measure of its thickness using the Oculus Keratograph 5M instrument. This ranges from Grade 1 indicating very thin lipid layer to Grade 6 indicating very thick lipid layer.
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Bulbar Conjunctival Hyperaemia to the First Follow-Up 1 Month After Baseline
Automated objective grading of the bulbar conjunctival redness using the Oculus Keratograph 5M instrument. This ranges from Grade 0 indicating no redness to Grade 4 indicating substantial redness.
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Bulbar Conjunctival Hyperaemia to the Second Follow-Up 1 Month After the First Follow-Up
Automated objective grading of the bulbar conjunctival redness using the Oculus Keratograph 5M instrument. This ranges from Grade 0 indicating no redness to Grade 4 indicating substantial redness.
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Blink Rate to the First Follow-Up 1 Month After Baseline
Manual subjective count of the number of blinks using the Oculus Keratograph 5M instrument.
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Blink Rate to the Second Follow-Up 1 Month After the First Follow-Up
Manual subjective count of the number of blinks using the Oculus Keratograph 5M instrument.
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Fluorescein Corneal Staining to the First Follow-Up 1 Month After Baseline
Subjective grading of the amount of corneal staining using fluorescein instillation, cobalt blue light illumination and the Oxford grading scale. This ranges from 0 with no staining to 5 with intense staining.
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Fluorescein Corneal Staining to the Second Follow-Up 1 Month After the First Follow-Up
Subjective grading of the amount of corneal staining using fluorescein instillation, cobalt blue light illumination and the Oxford grading scale. This ranges from 0 with no staining to 5 with intense staining.
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Lissamine Green Bulbar Conjunctival Staining to the First Follow-Up 1 Month After Baseline
Subjective grading of the amount of bulbar conjunctival staining using lissamine green instillation, white light illumination and the Oxford grading scale. This ranges from 0 with no staining to 5 with intense staining.
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Lissamine Green Bulbar Conjunctival Staining to the Second Follow-Up 1 Month After the First Follow-Up
Subjective grading of the amount of bulbar conjunctival staining using lissamine green instillation, white light illumination and the Oxford grading scale. This ranges from 0 with no staining to 5 with intense staining.
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Lissamine Green Lid Wiper Epitheliopathy to the First Follow-Up 1 Month After Baseline
Subjective grading of the amount of lid wiper epitheliopathy using lissamine green instillation and white light illumination. This grading ranges from 0 with no lid wiper epitheliopathy to 4 with severe lid wiper epitheliopathy
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Lissamine Green Lid Wiper Epitheliopathy to the Second Follow-Up 1 Month After the First Follow-Up
Subjective grading of the amount of lid wiper epitheliopathy using lissamine green instillation and white light illumination. This grading ranges from 0 with no lid wiper epitheliopathy to 4 with severe lid wiper epitheliopathy
Time frame: First follow-up to 1 month after the first follow-up
Change from Baseline in Meibography Meiboscore to the First Follow-Up 1 Month After Baseline
Subjective grading of the amount of Meibomian gland loss using infrared imaging and the Pult meiboscore. This grading ranges from 0 with no gland loss to 4 with severe gland loss (Pult and Reide-Pult, 2013).
Time frame: Baseline to 1 month after baseline
Change from First Follow-Up in Meibography Meiboscore to the Second Follow-Up 1 Month After the First Follow-Up
Subjective grading of the amount of Meibomian gland loss using infrared imaging and the Pult meiboscore. This grading ranges from 0 with no gland loss to 4 with severe gland loss (Pult and Reide-Pult, 2013).
Time frame: First follow-up to 1 month after the first follow-up
Number of Participants with Dry Eye Disease at Baseline
The number of participants diagnosed with dry eye disease according to established clinical diagnostic criteria (Wolffsohn et al, 2017).
Time frame: At baseline
Number of Participants with Dry Eye Disease at First Follow-Up
The number of participants diagnosed with dry eye disease according to established clinical diagnostic criteria (Wolffsohn et al, 2017).
Time frame: At first follow-up 1 month after baseline
Number of Participants with Dry Eye Disease at SecondFollow-Up
The number of participants diagnosed with dry eye disease according to established clinical diagnostic criteria (Wolffsohn et al, 2017).
Time frame: At second follow-up 1 month after first follow-up
Plan to share: Yes — The investigators are planning to deposit deidentified datasets in a publicly and freely available data repository site.
Time frame: Data will be available at the end of the study before publication of the findings in a peer-reviewed journal.
Access criteria: The dataset will be publicly and freely available.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.
Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's planned 27 months is above that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aston University